2/11
04:27 pm
iova
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026 [Yahoo! Finance]
Low
Report
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026 [Yahoo! Finance]
2/11
04:05 pm
iova
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026
Low
Report
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026
2/7
09:31 am
iova
Assessing Iovance Biotherapeutics (IOVA) Valuation After Recent Share Price Volatility [Yahoo! Finance]
Low
Report
Assessing Iovance Biotherapeutics (IOVA) Valuation After Recent Share Price Volatility [Yahoo! Finance]
2/6
11:12 am
iova
Iovance Biotherapeutics (IOVA) Gives Update on Revenue Guidance, Lung Cancer Cure [Yahoo! Finance]
Low
Report
Iovance Biotherapeutics (IOVA) Gives Update on Revenue Guidance, Lung Cancer Cure [Yahoo! Finance]
2/5
05:15 pm
iova
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
Medium
Report
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
2/5
08:04 am
iova
Iovance Biotherapeutics (NASDAQ:IOVA) had its "sell" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Medium
Report
Iovance Biotherapeutics (NASDAQ:IOVA) had its "sell" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
1/16
05:15 pm
iova
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Medium
Report
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
1/16
05:31 am
iova
Iovance Biotherapeutics (IOVA) Is Down 14.9% After Governance Scrutiny And Equity Raise Plan Is Revealed [Yahoo! Finance]
Medium
Report
Iovance Biotherapeutics (IOVA) Is Down 14.9% After Governance Scrutiny And Equity Raise Plan Is Revealed [Yahoo! Finance]
1/15
11:53 pm
iova
Iovance Biotherapeutics (IOVA) Valuation Check After Amtagvi Outlook Reaffirmation And Governance Concerns [Yahoo! Finance]
Medium
Report
Iovance Biotherapeutics (IOVA) Valuation Check After Amtagvi Outlook Reaffirmation And Governance Concerns [Yahoo! Finance]
1/15
02:36 pm
iova
Iovance Biotherapeutics, Inc. (IOVA): A Bull Case Theory [Yahoo! Finance]
Low
Report
Iovance Biotherapeutics, Inc. (IOVA): A Bull Case Theory [Yahoo! Finance]
1/12
03:31 pm
iova
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Iovance Biotherapeutics, Inc. (IOVA), Nutex Health, Inc. (NUTX), Lantheus Holdings, Inc. (LNTH), and Molina Healthcare, Inc. (MOH)
Low
Report
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Iovance Biotherapeutics, Inc. (IOVA), Nutex Health, Inc. (NUTX), Lantheus Holdings, Inc. (LNTH), and Molina Healthcare, Inc. (MOH)
12/31
11:21 am
iova
Barclays Adjusts Valuation Targets for Iovance Biotherapeutics (IOVA) Amid Biotech Sector Review [Yahoo! Finance]
Neutral
Report
Barclays Adjusts Valuation Targets for Iovance Biotherapeutics (IOVA) Amid Biotech Sector Review [Yahoo! Finance]
12/29
12:52 am
iova
Iovance Biotherapeutics: Bright Prospects For 2026 [Seeking Alpha]
Low
Report
Iovance Biotherapeutics: Bright Prospects For 2026 [Seeking Alpha]
12/24
06:15 am
iova
Iovance Biotherapeutics (NASDAQ:IOVA) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Low
Report
Iovance Biotherapeutics (NASDAQ:IOVA) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
12/19
05:15 pm
iova
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
High
Report
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
12/17
07:06 am
iova
Iovance Biotherapeutics (NASDAQ:IOVA) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
High
Report
Iovance Biotherapeutics (NASDAQ:IOVA) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
11/24
07:19 am
iova
Iovance Biotherapeutics (NASDAQ:IOVA) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
High
Report
Iovance Biotherapeutics (NASDAQ:IOVA) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
11/21
05:15 pm
iova
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
High
Report
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)